non-dilutive financing

• 

  Capricor’s Deramiocel Voted Down 9-3 by FDA Advisory Panel

  Nine advisory committee members looked at the same trial data Capricor called a win and voted against it. The 9-3 result on July 29 didn’t kill Capricor’s Duchenne muscular dystrophy program, but it added a real question mark to a therapy the company insists already cleared its bar. INmune Bio spent the same stretch doing…

  read more